AMR Fund and Global Cohorts Working to Prevent Another Pandemic

The AMR Action Fund, CARB-X, BEAM Alliance and a select group of life sciences companies are going all-in to develop novel antibiotics to stop the escalating epidemic of antimicrobial resistance (AMR) from becoming a full-fledged pandemic that could turn back the clock on medical treatment as we know it.

“Antibiotic resistance is like deferred maintenance on a key piece of infrastructure for society. We’ve underinvested in it for decades and gotten away with it because what we had before worked pretty well, but at some point, we could have something catastrophic,” said Kevin Outterson, Executive Director of CARB-X, a global non-profit partnership launched in 2016, whose mission is to tackle antimicrobial resistance.

According to the Centers for Disease Control and Prevention (CDC), more than 35,000 Americans perish each year from antibiotic-resistant infections, and estimates have AMR claiming the lives of as many as 10 million globally by 2050.